KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Net Margin (2016 - 2026)

NovoCure's Net Margin history spans 13 years, with the latest figure at 40.87% for Q1 2026.

  • On a quarterly basis, Net Margin fell 1873.0% to 40.87% in Q1 2026 year-over-year; TTM through Mar 2026 was 25.66%, a 75.0% increase, with the full-year FY2025 number at 20.79%, up 708.0% from a year prior.
  • Net Margin hit 40.87% in Q1 2026 for NovoCure, down from 14.05% in the prior quarter.
  • Over the last five years, Net Margin for NVCR hit a ceiling of 3.38% in Q1 2022 and a floor of 45.55% in Q2 2023.
  • Historically, Net Margin has averaged 27.54% across 5 years, with a median of 25.28% in 2025.
  • Biggest five-year swings in Net Margin: crashed -4005bps in 2023 and later surged 2683bps in 2025.
  • Tracing NVCR's Net Margin over 5 years: stood at 29.05% in 2022, then dropped by -21bps to 35.19% in 2023, then decreased by -16bps to 40.88% in 2024, then soared by 66bps to 14.05% in 2025, then tumbled by -191bps to 40.87% in 2026.
  • Business Quant data shows Net Margin for NVCR at 40.87% in Q1 2026, 14.05% in Q4 2025, and 22.29% in Q3 2025.